Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin in High-risk Compensated Cirrhosis
NCT03654053Phase 3Active, not recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cirrhosis comparing Simvastatin with Placebo (2 arms). Primary endpoint: Survival free from hepatic decompensation at 24 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
simvastatin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on NCT03654053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654053.